LabCorp Buying Orchid Cellmark for $85.4M | GenomeWeb

By a GenomeWeb Staff Reporter

NEW YORK (GenomeWeb News) – Laboratory Corporation of America has signed a definitive agreement to purchase Orchid Cellmark for $85.4 million, the two firms announced today.

Under the terms of the deal, LabCorp will purchase 30.5 million outstanding shares of Orchid Cellmark, including options, at $2.80 per share. Less Orchid Cellmark's cash and cash equivalents, and available for sale securities as of Dec. 31, 2010, the price of the deal is about $65.6 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.